Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 400

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 400
---
) who is a beneficial owner of more than 5% of our outstanding shares of common stock or is expected to be the beneficial owner of more than 5% of ParentCo’s outstanding shares of common stock following the closing;

•

each of Iris’s current named executive officers and directors;

•

each person who will become a named executive officer or a director of ParentCo upon the consummation of the Business Combination;

•

all of Iris’s current executive officers and directors as a group; and

•

all of ParentCo’s executive officers and directors as a group after the consummation of the Business Combination.

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. The table below does not include the shares of Iris Class A Common Stock underlying the private placement warrants held by the Sponsor, the Public Warrants to be issued at the closing because these securities are not exercisable within 60 days of this proxy statement/prospectus. Shares of common stock issuable pursuant to options or warrants are deemed to be outstanding for purposes of computing the beneficial ownership percentage of the person or group holding such options or warrants but are not deemed to be outstanding for purposes of computing the beneficial ownership percentage of any other person.

In the table below, beneficial ownership of Iris before the Business Combination is based on 7,074,477 shares of Iris Class A Common Stock outstanding as of January 2, 2025. The table below does not include the shares of Iris Class A Common Stock underlying the private placement warrants or the Public Warrants because these securities are not exercisable within 60 days of January 2, 2025.

The expected beneficial ownership percentages set forth in the table below with respect to ParentCo Common Stock following the Business Combination do not take into account: (i) the issuance of any shares (or options to acquire shares) under the Incentive Plan, (ii) the issuance of any shares upon the exercise of warrants to purchase up to a total of 6,900,000 shares of ParentCo Common Stock that will be outstanding following the Business Combination or (iii) the issuance of shares upon the exercise of 835,555 Private Warrants outstanding held by Cantor. If the actual facts are different than these assumptions (which they are likely to be), the percentage ownerships in Parent